Evotec Completes Acquisition Of Controlling Majority Stake In Research Support International Private Limited (RSIPL)

Evotec AG announced recently that the acquisition of the controlling majority stake of Research Support International Private Limited ("RSIPL") has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

The purchase price for the 70% controlling majority stake payable, before adjustments, to DIL Limited, India, is EUR 2.8 million in cash, a portion of which includes a potential earn-out. Evotec has a call option to purchase the remaining 30% from DIL in the future in the event of a change of control.

RSIPL, located in Thane near Mumbai, was founded in 2004 and currently employs approximately 160 employees. The company is providing Drug Discovery & Development services. RSIPL is a vibrant organization committed to provide a strong & reliable fundamental research platform to enable its customers to accelerate their drug discovery programs efficiently and cost effectively. RSIPL uses its world class infrastructure and facilities to synthesis virtually all types of organic compounds from milligram to kilogram scale. RSIPL was conferred the "Partner of Choice in Contract Research - Chemistry Based Services" award for the year 2007 by Frost & Sullivan in recognition of its experience in offering organic synthesis services to pharmaceutical and biotech customers worldwide.

Following the transaction, RSIPL will be integrated, into the value chain of Evotec's operations in Hamburg (Germany), Abingdon (UK) and Singapore. The members of the Management Board of Evotec AG, Dr Werner Lanthaler, Dr Mario Polywka and Dr Klaus Maleck, have been appointed as members of the Board of Directors of Evotec India together with two representatives from DIL.

This transaction represents an important capacity expansion for Evotec. It adds a complementary drug discovery operation and capability in the field of science-driven chemistry work in India to Evotec's already world-leading discovery platform and efficiently increases its ability to deliver high quality, know-how driven drug discovery and development services to its partners on a global scale.

SOURCE: N/A